Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
IRVINE, Calif., May 24, 2013 /PRNewswire/ — Andrew Technologies applauds the courage of actress Angelina Jolie and reporter Zoraida Sambolin of CNN to go public about their own personal experiences with breast cancer. This terrible disease has devastated the lives of many women and some men; and left many women with concerns about their perceived diminished femininity. Since HydraSolve® Lipoplasty System from Andrew Technologies is now the first FDA-cleared liposuction device for autologous fat transfer; it may offer a more natural alternative for those who seek to reconstruct their breasts after cancer.
Dr. Jeffrey Hartog at Bougainvillea Clinique in Winter Park, FL www.lookandfeelbetter.com has much experience with using autologous fat for breast reconstruction after cancer and is now using the new HydraSolve® system for fat transfer. Interestingly, Dr. Hartog decided to add breast reconstruction with autologous fat into his practice when his own wife, Michelle Hartog, RN, was diagnosed with breast cancer in 2011. Michelle Hartog explained, “For me, autologous fat transfer was the best choice after considering all the options.” Since then, Dr. Hartog has conducted numerous autologous fat breast reconstruction procedures. He added, “I find fat to be simply the most natural approach to breast reconstruction, without additional scarring and significantly lower risk of complications.” As for incorporating HydraSolve® into his autologous fat procedures, Dr. Hartog stated, “HydraSolve delivers very pure fat that is simple to process and injects easily into the breast tissue for reconstruction. We are still early in the adoption of this new technology, but it appears to be a great option for fat transfer.”
HydraSolve® is a novel liposuction device based on the same patented Tissue Liquefaction Technology(TM) that was launched in 2003 by Alcon as the AquaLase® Liquefaction Device, a modality on the Infiniti Vision System, for precision cataract surgery. HydraSolve® combines natural saline solution with low levels of pressure and temperature, to liquefy only targeted fat tissue. Because fat tissue is liquefied, the cutting of fat by forceful thrusts of the cannula is no longer required. The specially designed HydraSolve® cannula is manufactured with aperture edges that have a rounded radius of curvature that do not cut tissue. It is the energized saline stream, inside the cannula, that liquefies targeted fat tissue while preserving blood vessels, nerves and connective tissue integrity. HydraSolve® achieves liquefaction of fat tissue by cell disaggregation, not by emulsification and the lysing of cell membranes. HydraSolve® is now FDA-cleared for autologous fat transfer, the use of one’s own fat for rejuvenation or augmentation. The HydraSolve® Lipoplasty System is designed to contour the body by removing localized deposits of excess fat and is not intended to treat obesity. Liposuction is a surgical procedure that has risks similar to other minimally invasive cosmetic surgeries, see our web site for details www.hydrasolve.com.
Dr. Mark S. Andrew, Founder and Chief Scientific Officer of Andrew Technologies stated, “We designed HydraSolve® to be the best system for liposuction, offering improved recovery for patients and greater efficiency for surgeons. We are thrilled to also provide the first liposuction device FDA cleared for fat transfer and hope that we can eventually improve the lives of many future breast cancer patients.”
About Andrew Technologies, LLC
Andrew Technologies, founded in 2007, is a medical technology company committed to improving patients’ lives through body aesthetics and pursuit of surgical applications of Tissue Liquefaction Technology. Andrew Technologies is a venture capital funded company based in Orange County, CA and Haddonfield, NJ. Our primary investors are WFD Ventures http://www.wfdventures.com/ and NJTC Venture Fund http://www.njtcvc.com/.
SOURCE Andrew Technologies
